Suppr超能文献

高度同工型选择性 p21 激活激酶 4 抑制剂的精确设计:通过分子动力学模拟和结合自由能计算深入了解选择性机制的计算见解。

Precise design of highly isoform-selective p21-activated kinase 4 inhibitors: computational insights into the selectivity mechanism through molecular dynamics simulation and binding free energy calculation.

机构信息

Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang PR China.

出版信息

J Biomol Struct Dyn. 2020 Aug;38(13):3825-3837. doi: 10.1080/07391102.2019.1664330. Epub 2019 Sep 15.

Abstract

Understanding the selectivity mechanisms of inhibitors towards highly similar protein kinases is the first step in discovering new selective candidate for satisfactory safety profile. P21-activated kinases (PAKs) are pertain to a family of serine/threonine (Ser/Thr) protein kinases, which are the first Rho family GTPase-regulated kinases identified and served as important downstream mediators of Ras-Rac and Cdc42 function. Among PAKs, PAK4 is emerging as a promising target for cancer treatment. Since the PAK2 inhibition correlates with increased acute cardiovascular toxicity, which may be enhanced by PAK1 inhibitor, selective inhibition of PAK4 over PAK1 is crucial in discovering safe anticancer candidates with optimal therapeutic efficacy. While the conserved ATP-binding pockets of both PAK1/4 make it challenging to discriminating selective inhibitors between PAK1 and PAK4, thus the selectivity mechanism of PAK1/4 inhibitors will be explored in this present study through, computational strategies which combine molecular docking, structural comparison, molecular dynamics simulation and molecular mechanics/generalized Born surface area calculation. The research would provide valuable insight into the selectivity mechanism of PAK4 inhibitors over PAK1 and thus be helpful for designing selective PAK4 inhibitors.Communicated by Ramaswamy H. Sarma.

摘要

了解抑制剂对高度相似的蛋白激酶的选择性机制是发现具有满意安全性特征的新选择性候选物的第一步。P21 激活激酶(PAKs)属于丝氨酸/苏氨酸(Ser/Thr)蛋白激酶家族,是首批被鉴定的 Rho 家族 GTPase 调节激酶,作为 Ras-Rac 和 Cdc42 功能的重要下游介质。在 PAKs 中,PAK4 作为癌症治疗的一个有前途的靶点正在出现。由于 PAK2 抑制与急性心血管毒性增加相关,而 PAK1 抑制剂可能增强这种毒性,因此,选择性抑制 PAK4 而不是 PAK1 对于发现具有最佳治疗效果的安全抗癌候选物至关重要。尽管 PAK1/4 的保守 ATP 结合口袋使得区分 PAK1 和 PAK4 的选择性抑制剂具有挑战性,但通过结合分子对接、结构比较、分子动力学模拟和分子力学/广义 Born 表面积计算的计算策略,本研究将探索 PAK1/4 抑制剂的选择性机制。该研究将深入了解 PAK4 抑制剂对 PAK1 的选择性机制,从而有助于设计选择性 PAK4 抑制剂。Ramaswamy H. Sarma 通讯。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验